Literature DB >> 10715431

Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.

T Kato1, T Tokoro, Y Namii, T Kobayashi, S Hayashi, I Yokoyama, S Morimoto, M Chan, N Giannetti, S A Hunt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10715431     DOI： 10.1016/s0041-1345(99)00971-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  3 in total

Review 1.  Pharmacotherapy of hyperlipidemia in pediatric heart transplant recipients: current practice and future directions.

Authors:  Clifford Chin; Daniel Bernstein
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

Authors:  H S Malhotra; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Ethnic disparities in cardiac transplantation: opportunities to improve long-term outcomes in all cardiac transplant recipients.

Authors:  Jeremy Kobulnik; Yasbanoo Moayedi; Douglas Greig
Journal:  Isr J Health Policy Res       Date:  2019-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.